| 摘要 |
The present disclosure provides methods for treating B cell lymphomas using a combination of anti-CD19 and anti-CD20 antibodies. Such methods provide therapeutic advantages over single antibody therapies, including prolonged anti-tumor activity and/or reduced dosages. |
